REMEVi review
A genuinely transparent tiered-pricing shop — as low as $149/mo semaglutide or $199/mo tirzepatide on the annual plan — with press mentions and bilingual support, though the oral tablet's own pricing wasn't fully itemized.
- HSA / FSA-eligible
- Editor-vetted
- No insurance needed
REMEVi at a glance
- Semaglutide
- $149-219/mo depending on plan length
- Tirzepatide
- $199-319/mo depending on plan length
- Coverage
- All 50 states + DC
- Start
- Not published
How we scored REMEVi
Each factor is scored from REMEVi's real pricing, disclosures and intake flow, then combined into the 66/100 Rx-Readiness Score by the same weighted six-factor framework we apply to every provider — never nudged by whether a provider pays us.
Not published — scored on the non-disclosure.
Explicitly states the price never climbs with dose, with three real tiers shown for both molecules before intake.
Not stated either way — scored on the gap.
All 50 states plus DC, stated outright.
Both molecules plus an oral option, but no brand-name fallback.
The cheapest tier requires a 52-week prepaid commitment; no cancellation policy for that commitment was found on the pages checked.
How we verified this review
- Last verified
- August 2026
- Confidence
- medium
- Primary source
- remevihealth.com
Sourced from WLR's provider directory, independently re-verified live on remevihealth.com (2026-08-02) — both drugs' full three-tier pricing confirmed directly on their own pages. The oral-tablet option is real but its own separate price tier was not itemized on the pages checked; treated it as matching the injectable monthly rate pending a closer look.
What to expect when you sign up
We walked REMEVi's public signup funnel (August 2026) — a first-hand look at the flow. We don't create accounts, enter medical data, or complete checkout, so this is what any visitor sees, not a patient outcome.
- 1Each drug's own page shows a 'From $X/mo' headline, then a plan-length picker (Monthly / 12-Week / 52-Week) with real prices for each tier
- 2The page states '6 services · $400+/mo bought separately' are bundled into the number
- 3A bilingual (English/Spanish) support model is advertised, plus press mentions (AP, USA Today, Fortune, Reuters) and Google/Trustpilot ratings
What we noticed
- Genuinely transparent tiered pricing — all three plan lengths for both molecules are visible without starting an intake
- The site explicitly states the per-month price 'never climbs with your dose,' a real flat-pricing claim
- Licensed in all 50 states plus DC per its own claim; LegitScript and HIPAA badges displayed; cold-chain shipping every 4 weeks
Pricing
Prices re-verified
| Medication | Monthly | Plan |
|---|---|---|
| Compounded semaglutide | $219 | MonthlyPrice never climbs with dose. |
| Compounded semaglutide | $189 | 12-Week plan |
| Compounded semaglutide | $149 | 52-Week plan (best value)About $7.82/day on the monthly term equivalent, per the site's own framing. |
| Oral semaglutide | $219 | Daily tablet optionSame weekly-injection pricing structure offered as a daily oral tablet for needle-averse patients; exact oral tier pricing wasn't itemized separately on the page checked. |
| Compounded tirzepatide | $319 | Monthly |
| Compounded tirzepatide | $249 | 12-Week plan |
| Compounded tirzepatide | $199 | 52-Week plan (best value)Billed as $2,587 total, framed on-site as 'save $1,560' against the monthly rate. |
Swipe the table to see plan details →
HSA/FSA is commonly accepted for GLP-1 telehealth — check your plan. Prices reflect REMEVi's public disclosures at last review and change often; confirm the current number on REMEVi's own site.
What we like
- All three plan-length tiers for both molecules are visible on the public site, no intake required
- Explicitly states the price never climbs with dose — a real flat-pricing claim, not just a marketing line
- Bilingual (English/Spanish) support with WhatsApp, plus press mentions (AP, USA Today, Fortune, Reuters)
- Licensed in all 50 states plus DC; LegitScript and HIPAA badges displayed
The caveats
- No brand-name (FDA-approved) option
- The oral tablet option's own separate pricing tier wasn't itemized on the pages checked
- No published time-to-first-dose or statement on whether a video visit is required
- Cheapest tier requires a 52-week upfront commitment to reach $149/mo (sema) or $199/mo (tirz); the monthly rate is meaningfully higher at $219/$319
REMEVi for working moms: our verdict
A genuinely transparent tiered-pricing shop — as low as $149/mo semaglutide or $199/mo tirzepatide on the annual plan — with press mentions and bilingual support, though the oral tablet's own pricing wasn't fully itemized. It runs about $149/month, flat across every dose — toward the affordable end of what we track.
We weigh REMEVi the way working moms actually have to: not just the monthly line on your budget, but how fast you can start without a scheduled video visit and a flat monthly price that doesn't climb as your dose does — the parts a generic weight-loss review skips.
What REMEVi actually costs
- Compounded semaglutide — Monthly: $219/mo
- Compounded semaglutide — 12-Week plan: $189/mo
- Compounded semaglutide — 52-Week plan (best value): $149/mo
- Oral semaglutide — Daily tablet option: $219/mo
- Compounded tirzepatide — Monthly: $319/mo
- Compounded tirzepatide — 12-Week plan: $249/mo
That sits below the roughly $177 median ongoing price across the providers we track for working moms — a real cost advantage.
The medications REMEVi prescribes
REMEVi prescribes semaglutide and tirzepatide — the two molecules with the strongest published weight-loss outcomes, and having both on one account matters because you can switch between them without re-enrolling or hunting for a new provider mid-plan. These are compounded formulations from a licensed pharmacy — the reason the price stays down — but compounded GLP-1s aren't FDA-approved finished products the way Wegovy and Zepbound are.
A needle-free oral or sublingual option is on the menu, which draws in working moms who've been avoiding injections — just set expectations: oral and buccal delivery of these peptides is far less studied than the injectable versions the trials used.
Where REMEVi fits — and where it doesn't — for working moms
A good fit if…
- the monthly line on your budget is a real barrier and you want a low, predictable number.
- you want a flat price that doesn't climb every time you titrate up a dose.
- nationwide access matters — a move for work or family shouldn't interrupt care.
Look elsewhere if…
- you specifically want an FDA-approved brand pen and insurance navigation.
- you want frictionless cancellation and no prepay lock-in — the exit terms are the weak point here.
- you'd rather the most predictable place to start and pause — that's what our #1 pick, CoreAge Rx, is built for.
Trust, safety, and the fine print
Our confidence is moderate — the core facts check out, but some details (per-state availability, program mechanics) aren't fully public. As with any compounded GLP-1, the most useful thing working moms can do is confirm which licensed pharmacy fills the prescription and what's in the formulation — we explain how we weigh oversight in our scoring methodology.
A standing caveat for working moms: GLP-1 medications aren't established as safe during pregnancy or breastfeeding, and every label advises against use. Nothing here changes that — plan the timing with your own clinician.
The bottom line
REMEVi is a genuine value play — weigh it on how fast you can start without a scheduled video visit and a flat monthly price that doesn't climb as your dose does against the alternatives below. For most working moms, CoreAge Rx remains the stronger all-round fit — see why it tops our ranking.
The bottom line for working moms
Best for: Working moms who want to see every plan-length tier before committing and value bilingual (EN/ES) support.
Alternatives to REMEVi
Providers we have a referral relationship with, ordered by Rx-Readiness Score — highest first. A fee never moves a score, but it does decide who appears here, so this is not the full list: see the complete ranking.
- Visit CoreAge RxRx-Readiness95100CoreAge RxOur #1 pick
The shortlist pick: one flat price that doesn't climb as your dose does, both molecules on a single plan, and a nationwide async intake you can finish on a break.
- Visit Trimi HealthRx-Readiness88100
The price-first partner: some of the lowest flat, all-inclusive compounded pricing we track, nationwide and async — strong if the monthly number is your deciding factor and you read the annual-prepay fine print.
- Visit Telos RxRx-Readiness86100
A fast, fully async start with a needle-free sublingual tirzepatide option and — a genuine upgrade since our last check — flat pricing stated in writing. The catch is a state list it still won't publish.
Keep comparing REMEVi
Head-to-head & alternatives
REMEVi, answered
- How much does REMEVi cost?
- As last verified, REMEVi's compounded pricing starts around $149/month ($149-219/mo depending on plan length semaglutide, $199-319/mo depending on plan length tirzepatide). Confirm the current, all-in price on REMEVi's own site before you commit.
- Can I start REMEVi without a scheduled video visit?
- REMEVi involves more clinician touchpoints (and, in some cases, a scheduled visit), so it isn't the fastest async start. If a no-video signup is your priority, our #1 pick is built for it.
- Does REMEVi offer both semaglutide and tirzepatide?
- Yes — REMEVi offers both molecules, so you can switch without re-enrolling. Tirzepatide's dual GIP/GLP-1 action posts the strongest published weight-loss numbers.
- Where does REMEVi rank for working moms?
- REMEVi scores 66/100 on our Rx-Readiness Score (rank #27), which weights six factors led by speed to first dose and flat pricing. Our #1 pick, CoreAge Rx, leads the ranking — see how they compare.
Pricing, states and verification reflect REMEVi's public disclosures at last review; the Rx-Readiness Score is our editorial judgment per the published methodology. This is background reading, not medical advice — GLP-1 medications are not established as safe in pregnancy or breastfeeding. See our medical disclaimer and how we're funded.